Valeria Cuccarini1, Luigi Antelmi1, Bianca Pollo2, Rosina Paterra3, Chiara Calatozzolo2, Anna Nigri1, Francesco DiMeco4, Marica Eoli3, Gaetano Finocchiaro3, Greta Brenna5, Irene Tramacere5, Maria Grazia Bruzzone1, Elena Anghileri6. 1. Unit of Neuroradiology, Fondazione Irccs Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy. 2. Neuropathology, Fondazione Irccs Istituto Neurologico Carlo Besta, Milan, Italy. 3. Unit of Molecular Neuro-Oncology, Fondazione Irccs Istituto Neurologico Carlo Besta, Milan, Italy. 4. Department Neurosurgery Department, Fondazione Irccs Istituto Neurologico Carlo Besta, Milan, Italy. 5. Department of Research and Clinical Development, Scientific Directorate, Fondazione Irccs Istituto Neurologico Carlo Besta, Milan, Italy. 6. Unit of Molecular Neuro-Oncology, Fondazione Irccs Istituto Neurologico Carlo Besta, Milan, Italy. elena.anghileri@istituto-besta.it.
Abstract
Isocitrate dehydrogenase 1/2 (IDH1/2) mutations are often detected in lower-grade gliomas (LGG) and result into 2-hydroxyglutarate (2HG) synthesis. Prior studies showed that 2HG can be detected in vivo using magnetic resonance spectroscopy (MRS), but its accuracy and translational impact are still under investigation. PURPOSE: To investigate the clinical feasibility of MRS for in vivo detection and quantification of 2HG on consecutive treatment-naïve suspect LGG patients and to compare MRS accuracy with tissue IDH1/2 analysis. METHODS: MRS spectra at 3 T were acquired with 1H-MRS single-voxel PRESS 2HG-tailored sequences with TE 30 (group 1) or TE 97 (groups 2A and B). Voxel sizes were 1.5 × 1.5 × 1.5 cm3 for group 1 (n = 13) and group 2A (n = 14) and 2 × 2 × 2 cm3 for group 2B (n = 32). Multiple metabolites' concentrations were analyzed with LCModel. Tumors were assessed for IDH status and main molecular markers. 2HG levels in urine/blood were measured by liquid chromatography-mass spectrometry. RESULTS: The larger voxel TE 97 sequence resulted in highest specificity (100%), sensitivity (79%), and accuracy (87%). Urine and blood 2HG did not result predictive. CONCLUSION: Our data confirm that 2 × 2 × 2-cm3 voxel TE 97 MRS shows high accuracy for 2HG detection, with good sensitivity and 100% specificity in distinguishing IDH mutant gliomas. Main limits of the technique are small tumor volume and low cellularity. Integrating 2HG-MRS with other metabolites may help non-invasive diagnosis of glioma, prognostic assessment, and treatment planning in clinical setting.
Isocitrate dehydrogenase 1/2 (IDH1/2) mutations are often detected in lower-grade gliomas (LGG) and result into 2-hydroxyglutarate (2HG) synthesis. Prior studies showed that 2HG can be detected in vivo using magnetic resonance spectroscopy (MRS), but its accuracy and translational impact are still under investigation. PURPOSE: To investigate the clinical feasibility of MRS for in vivo detection and quantification of 2HG on consecutive treatment-naïve suspect LGG patients and to compare MRS accuracy with tissue IDH1/2 analysis. METHODS: MRS spectra at 3 T were acquired with 1H-MRS single-voxel PRESS 2HG-tailored sequences with TE 30 (group 1) or TE 97 (groups 2A and B). Voxel sizes were 1.5 × 1.5 × 1.5 cm3 for group 1 (n = 13) and group 2A (n = 14) and 2 × 2 × 2 cm3 for group 2B (n = 32). Multiple metabolites' concentrations were analyzed with LCModel. Tumors were assessed for IDH status and main molecular markers. 2HG levels in urine/blood were measured by liquid chromatography-mass spectrometry. RESULTS: The larger voxel TE 97 sequence resulted in highest specificity (100%), sensitivity (79%), and accuracy (87%). Urine and blood 2HG did not result predictive. CONCLUSION: Our data confirm that 2 × 2 × 2-cm3 voxel TE 97 MRS shows high accuracy for 2HG detection, with good sensitivity and 100% specificity in distinguishing IDH mutant gliomas. Main limits of the technique are small tumor volume and low cellularity. Integrating 2HG-MRS with other metabolites may help non-invasive diagnosis of glioma, prognostic assessment, and treatment planning in clinical setting.
Authors: Ovidiu C Andronesi; Otto Rapalino; Elizabeth Gerstner; Andrew Chi; Tracy T Batchelor; Dan P Cahill; A Gregory Sorensen; Bruce R Rosen Journal: J Clin Invest Date: 2013-09-03 Impact factor: 14.808
Authors: Ovidiu C Andronesi; Grace S Kim; Elizabeth Gerstner; Tracy Batchelor; Aria A Tzika; Valeria R Fantin; Matthew G Vander Heiden; A Gregory Sorensen Journal: Sci Transl Med Date: 2012-01-11 Impact factor: 17.956
Authors: Zhongxu An; Sandeep K Ganji; Vivek Tiwari; Marco C Pinho; Toral Patel; Samuel Barnett; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Changho Choi Journal: Magn Reson Med Date: 2016-07-25 Impact factor: 4.668
Authors: Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher Journal: Nat Med Date: 2012-01-26 Impact factor: 53.440
Authors: Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan Journal: Nature Date: 2012-02-15 Impact factor: 69.504
Authors: Amir T Fathi; Brian V Nahed; Seth A Wander; A John Iafrate; Darrell R Borger; Ranliang Hu; Ashraf Thabet; Daniel P Cahill; Ashley M Perry; Christelle P Joseph; Alona Muzikansky; Andrew S Chi Journal: Oncologist Date: 2016-02-01 Impact factor: 5.837
Authors: L McCarthy; G Verma; G Hangel; A Neal; B A Moffat; J P Stockmann; O C Andronesi; P Balchandani; C G Hadjipanayis Journal: AJNR Am J Neuroradiol Date: 2022-05-26 Impact factor: 4.966